March 23, 2010
The National Law Journal
The U.S. Court of Appeals for the Federal Circuit recently issued an en banc decision in Ariad Pharmaceuticals Inc. v. Eli Lilly and Co. upholding an earlier ruling that patent applications must contain a specific “written description” of the claimed invention in addition to enabling language explaining how to make and use the invention. Because the written-description mandate requires applicants to provide greater detail about what the invention does, it can reduce the scope of patent protection. The March 22, 2010 decision also upheld the court’s 2009 ruling that Ariad’s patent claims were invalid because they failed to meet the written-description requirement. Finnegan partner Charles Lipsey argued the case for Eli Lilly.
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.